You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 15, 2026

Claims for Patent: 11,738,120

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,738,120

Title:	Synthesis of taurolidine, purity profiles and polymorphs
Abstract:	Improved methods for synthesizing taurolidine, improved compositions or formulations comprising taurolidine and methods for reducing an amount of impurities in taurolidine are provided herein, among other things. The taurolidine may be substantially free of impurities. The taurolidine may be a polymorph, for example, Polymorph A or Polymorph B. The composition or formulation may comprise Low-Molecular-Weight (LMW) Heparin.
Inventor(s):	Reyes M. Berrios
Assignee:	Cormedix Inc
Application Number:	US17/721,699
Patent Claims:	1. A locking solution composition for treating and reducing infection and flow reduction in blood catheters, wherein the composition comprises a solution of: a. taurolidine, wherein all or substantially all of the taurolidine was obtained from a polymorph of the taurolidine, wherein the polymorph is Polymorph A characterized by an X-ray powder diffraction (XRPD) plot shown in FIG. 2 ; b. a biologically acceptable acid; and c. low concentration heparin, in a concentration of 50 to 2500 units per mL of the composition. 2. The composition of claim 1, wherein the composition is completely free from hexane and toluene. 3. The composition of claim 1 wherein the biologically acceptable acid is chosen from the group consisting of citric acid and lactic acid. 4. The composition of claim 1 wherein low concentration heparin is in the range of 50 to 1750 units per mL. 5. The composition of claim 1 wherein low concentration heparin is in the range of 50 to 500 units per mL. 6. The composition of claim 1 wherein the low concentration heparin is in the range 50 to 150 units per mL. 7. The composition of claim 1, wherein the heparin is low molecular weight (LMW) heparin. 8. A locking solution composition for treating and reducing infection and flow reduction in blood catheters, wherein the composition comprises a solution of: a. taurolidine, wherein all or substantially all of the taurolidine was obtained from a polymorph of the taurolidine, wherein the polymorph is Polymorph B characterized by an X-ray powder diffraction (XRPD) plot shown in FIG. 3 ; b. a biologically acceptable acid; and c. low concentration heparin, in a concentration of 50 to 2500 units per mL of the composition. 9. The composition of claim 8, wherein the composition is completely free from hexane and toluene. 10. The composition of claim 8 wherein the biologically acceptable acid is chosen from the group consisting of citric acid and lactic acid. 11. The composition of claim 8 wherein low concentration heparin is in the range of 50 to 1750 units per mL. 12. The composition of claim 8 wherein low concentration heparin is in the range of 50 to 500 units per mL. 13. The composition of claim 8 wherein the low concentration heparin is in the range 50 to 150 units per mL. 14. The composition of claim 8, wherein the heparin is low molecular weight (LMW) heparin. 15. A locking solution composition for treating and reducing infection and flow reduction in blood catheters, wherein the composition comprises a solution of: a. taurolidine, wherein all or substantially all of the taurolidine was obtained from polymorphs of the taurolidine, wherein the polymorphs are Polymorph A characterized by an X-ray powder diffraction (XRPD) plot show in FIG. 2 and Polymorph B characterized by an X-ray powder diffraction (XRPD) plots shown in FIG. 3 ; b. a biologically acceptable acid; and c. low concentration heparin, in a concentration of 50 to 2500 units per mL of the composition. 16. The composition of claim 15, wherein the composition is completely free from hexane and toluene. 17. The composition of claim 15 wherein the biologically acceptable acid is chosen from the group consisting of citric acid and lactic acid. 18. The composition of claim 15 wherein low concentration heparin is in the range of 50 to 1750 units per mL. 19. The composition of claim 15 wherein low concentration heparin is in the range of 50 to 500 units per mL. 20. The composition of claim 15 wherein the low concentration heparin is in the range 50 to 150 units per mL. 21. The composition of claim 15, wherein the heparin is low molecular weight (LMW) heparin. 22. A locking solution composition for treating and reducing infection and flow reduction in blood catheters, wherein the composition comprises a solution of: a. taurolidine, wherein all or substantially all of the taurolidine was obtained from one or more polymorphs of the taurolidine, wherein the one or more polymorphs are selected from the group consisting of Polymorph A characterized by an X-ray powder diffraction (XRPD) plot shown in FIG. 2 and Polymorph B characterized by an X-ray powder diffraction (XRPD) plot shown in FIG. 3 ; and b. a biologically acceptable acid. 23. The composition of claim 22, wherein the composition is completely free from hexane and toluene. 24. The composition of claim 22, wherein the biologically acceptable acid is chosen from the group consisting of citric acid and lactic acid.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.